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ABSTRACT   
Hepatosplenic T-cell lymphoma (HSTL) is a rare entity mostly derived from γδ T cells that 
shows a fatal outcome. Its pathogenesis remains largely unknown. HSTL samples (7γδ, 2αβ) and 
the DERL2 HSTL-cell line were subject to combined gene expression profiling and array-based 
comparative genomic hybridization. Compared to other T-cell lymphomas, HSTL disclosed a 
distinct molecular signature irrespective of TCR cell lineage. Compared to PTCL,NOS and 
normal γδ cells, HSTL overexpressed genes encoding NK-cell associated molecules, oncogenes 
(FOS, VAV3), the Sphingosine-1-phosphatase receptor 5 involved in cell trafficking and the 
tyrosine kinase SYK, whereas the tumor suppressor gene AIM1 was among the most 
downexpressed. Methylation analysis of DERL2 cells demonstrated highly methylated CpG 
islands of AIM1 and decitabine treatment induced significant increase in AIM1 transcripts. 
Notably, Syk was demonstrated in HSTL cells with its phosphorylated form present in DERL2 
cells by Western blot, and in vitro DERL2 cells were sensitive to a Syk inhibitor. Genomic 
profiles confirmed recurrent isochromosome 7q (n=6/9) without alterations at 9q22 and 6q21 
containing SYK and AIM1 genes, respectively. The current study identifies a distinct molecular 
signature for HSTL and highlights oncogenic pathways which offer rationale for exploring new 
therapeutic options such as Syk inhibitors and demethylating agents.  
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INTRODUCTION  
Hepatosplenic T-cell lymphoma (HSTL), originally described as hepatosplenic γδ T cell 
lymphoma, is a rare lymphoma entity with peculiar clinical presentation - hepatosplenomegaly 
without significant lymphadenopathy - and pathological features -  intrasinusal/sinusoidal 
infiltration by neoplastic Τ cells in the bone marrow, spleen and liver1-3. The disease occurs 
predominantly in young adults, in association with a setting of long-term immunosuppression in 
solid organ transplant recipients or with prolonged antigenic stimulation 4. Cases have also been 
reported in children treated by azathioprine and infliximab for Crohn’s disease5. While most 
HSTL are derived from the γδ subset, a few similar cases with an αβ phenotype have also been 
described6,7, and the simplified designation “hepatosplenic T-cell lymphoma” was favored in the 
latest World Health Organization classification8. HSTL is associated with a recurrent 
isochromosome 7q and less often, trisomy 89, but its pathogenesis remains largely unknown.  
Despite relatively innocuous cytology, the disease is highly aggressive with an almost 
constant fatal outcome and a median overall survival barely exceeding one year4. Occasional long 
survivors have been reported and few patients respond to cytarabine or deoxycoformycin4,10. 
Therapeutic strategies curative in a significant proportion of other aggressive subtypes of 
lymphoma, have proved to be ineffective in HSTL and efficient treatment modalities remain to be 
defined. 
Over the past years, genome-wide molecular profiling studies have contributed significant 
insights to the pathobiology of several T-cell lymphoma entities11-14 and brought informative data 
on the multiple molecular subgroups in PTCL, not otherwise specified (PTCL,NOS)15,16. In that 
respect, data on HSTL are scarce13,17. In the current study, we analyzed a series of HSTL samples 
in relation to normal γδ cells, PTCL,NOS and extranodal NK/T-cell lymphoma, nasal-type 
(NKTCL), another entity derived from  cytotoxic lymphocytes of the innate immune system. The 
aim of the study was to (1) characterize the molecular signature of HSTL, (2) identify potential 
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candidate pathways relevant to pathogenesis, and (3) search for biomarkers useful in the 
diagnostic purposes or in the future targeted therapies. 
 
PATIENTS, MATERIALS AND METHODS 
Patient characteristics and tumor samples  
Nine HSTL patients with high quality RNA and/or DNA extracted from frozen tumor samples 
were selected for this study. All patients had spleen, liver and bone marrow involvement without 
lymphadenopathies. Three patients had been included in previous reports4,9. The main clinical, 
phenotypic and molecular characteristics are summarized in Table 1. The tumor samples, 
comprised six splenic tissue samples and three cell suspensions (from spleen, bone marrow and 
blood), two of which were enriched in tumor cells (samples HSTL_01 and HSTL_09). All cases 
were reviewed by three hematopathologists (L.d.L, Y.H. and P.G.) and diagnosed according to 
the WHO criteria8. The tumor cells had a CD3+, CD2+, CD5-, TiA1+, GzmB- 
immunophenotype and were negative for EBV. T-cell receptor (TCR )lineage was determined by 
immunohistochemistry and/or flow cytometry for TCRβ and TCRδ chain expression and by GC-
clamp multiplex PCR for TCRγ  and/or δ chain rearrangements ((PCR)-δ-DGGE procedure)18. In 
total, seven cases with a δTCR1+, βF1- immunophenotype and/or a biallelic rearrangement of the 
TCRδ chain18,19, were classified as γδ HSTL and two cases with a δTCR1-, βF1+ phenotype as 
αβ HSTL. Four of seven investigated cases disclosed isochromosome 7q. 
Twelve additional HSTL cases were selected for validations (10 formalin-fixed tissues for 
immunohistochemistry and 2 frozen samples for RT-PCR analyses).  
The study was approved by the institutional review board “Comité de Protection des Personnes 
Ile de France IX”, Créteil, France CPP N°08-009 (06/05/08). 
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Cell lines and normal γδ T cells  
Eight samples of normal peripheral blood activated γδ T cells (6 from Correia20 and 2 from 
Zhang21) and 3 samples of normal resting γδ T cells (from Correia20) were used for comparison. 
Normal γδ T cells sorted using magnetic anti-TCRγ/δ microbeads kit (Miltenyi Biotec, Bergisch 
Gladbach, Germany) from 3 spleens removed for benign conditions were also obtained for qRT-
PCR validation. DERL2, a γδ cell line derived from HSTL22, was cultured in IMDM 
supplemented with 2 mM L-glutamine and 20% heat-inactivated human serum (Invitrogen, 
Carlsbad, CA) in the presence of recombinant human interleukin (IL)-2 (100 U/ml, Laboratoires 
Chiron, Amsterdam). Centrifugated pellets of DERL2 cells were fixed in ethanol to construct 
paraffin-embedded blocks14. 
 
Microarray procedures 
Microarray analyses, from extraction to labeling and hybridization, were performed as previously 
reported11,14. 
 
Gene expression analyses 
HG-U133-plus-2.0 Affymetrix array data were obtained for nine HSTL and the DERL-2 cell line 
(Table 1) and deposited to ArrayExpress under accession number E-MTAB-638.  HG-U133-plus-
2.0 profiles of 42 PTCL-NOS, 23 AITL, 23 NKTCL and 3 HSTL previously reported by our 
group (E-TABM-783, E-TABM-702, n=40)11,14 and others (GSE19067, GSE6338, n=51)12,13 
were used for analyses. Control samples (8 activated γδ T-cells,  3 resting γδ T-cells, 18 B-cells, 
6 spleens and 9 lymph nodes) were collected by us (n=6) or from public sources (E-MEX-1601, 
GSE13906, GSE12195, GSE15271, GSE7307)20,21,23,24. Affymetrix raw data of all samples were 
normalized in batch using RMA algorithm. The clustering analysis of the 50 tumor samples from 
our series was performed as already described 14. We used moderate T-tests to identify genes 
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differentially expressed between two groups of samples and AUC criteria to identify discriminant 
genes. KEGG and Biocarta pathways (and related genes) were obtained from 
ftp://ftp.genome.ad.jp/pub/kegg/pathways/hsa and http://www.biocarta.com. Pathways were 
ranked according to the scores of three different algorithms including globaltest, SAM-GS and 
GSA. Methodological details are given in the Supplementary Materials and Methods (Method 
S1). 
 
Array-based comparative genomic hybridization 
DNAs extracted from 7 HSTL and DERL2 cell line were hybridized on Agilent Sureprint CGH 
array 4 x 180 k covering over 170,000 coding and non-coding human sequences. CGH array raw 
Cy3/Cy5 intensities were quantile normalized independently for each sample; smoothing was 
performed using tilingArray R package, copy number status (Gain/Loss) determination in the 
smoothed segments was done as previously reported14.  Details are given as supplemental 
(Method S1). 
 
Quantitative reverse-transcriptase PCR analysis of candidate genes 
The expression level of candidate genes (FOS, FOSB, AIM1, RHOB, ABCB1, VAV3, KIR3DS1, 
S1PR5) identified in gene expression analysis was determined by TaqMan® quantitative reverse-
transcriptase PCR (qRT-PCR) (Applied Biosystems, Foster City, CA) in 11 primary HSTL 
tumors (including the 9 cases submitted to GEP analysis), the DERL2 cell line and 3 normal 
splenic γδ T cell samples as control. All primers and probes were purchased from Applied 
Biosystems and the gene expression was measured using Mastercycler® ep realplex2S system 
(Eppendorf, Hamburg, Germany). Quantifications were done in duplicate and mean values and 
standard deviation were calculated for each transcript as previously described25.   
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Immunohistochemical analysis of selected candidate genes  
Immunohistochemistry was performed on deparaffinized tissue sections using a standard indirect 
avidin-biotin immunoperoxidase method. After appropriate antigen retrieval, sections were 
stained for FosB (Cell Signaling Technology, Danvers, MA); CD56, CD163 and GSTP1 
(Novocastra-Leica, Wetzlar, Germany);  β-catenin (BD Biosciences, San Diego, USA); Bcl-10 
(Zymed, San Francisco, USA), ICAM-1 (Atlas Antibodies, Stockolm, Sweden), VCAM-1 and 
Syk (Santa Cruz Biotechnology, Santa Cruz, USA), Blimp-1 (BioLegend UK Ltd, Cambridge, 
UK). For granzyme H (gzm H)(4G5) a tyramide signal amplification system was applied, as 
previously described14. Adequate controls were included. 
 
Methylation analysis of AIM1 
Two µg of genomic DNA were treated with bisulfite using the Epitect® Bisulfite Kit (Qiagen, 
Courtaboeuf, France) according to manufacturer’s protocol. Nested bisulfite-specific PCR for the 
2 CpG islands of AIM1 was performed on DERL2 cells DNA (details, primers and PCR 
programs used are given in Supplemental Methods (Method S1)). PCR products were cloned in 
plasmid using TOPO TA cloning kit for sequencing (Invitrogen). Ten clones for each CpG 
islands were screened and sequenced on the ABI 3130X1 genetic analyser (Applied Biosystems). 
 
5-Aza-2′-deoxycytidine  treatment of DERL2 cells 
DERL2 cells were treated with the demethylating agent 5-Aza-2′-deoxycytidine (Decitabine, 
Merck Chemicals, Nottingham, UK) at 10µM or 40µM for 96 hours (decitabine was added every 
24 hours) alone or in combination with 500 nM histone deacetylase inhibitor trichostatin A 
(TSA) (Sigma Aldrich, Saint-Quentin Fallavier, France). In the combined treatment (decitabine 
and TSA), cells were treated with 10 μM or 40 µM of decitabine for 96 hours (every 24 hours) 
followed by 500 nM of TSA for the last 24 hours. Total RNA was extracted and qRT-PCR was 
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performed to evaluate the re-expression of the demethylated gene AIM1 after decitabine 
treatment. In addition the number of apoptotic cells was determined by Annexin V+, 7AAD+ 
cells using a Cyan flow cytometer (Beckman Coulter, Villepinte, France). 
Immunoblot analysis  
Total cell proteins extracted from normal blood T cells [purified after CD2 magnetic beads 
selection and activated or not by CD3 (1µg/ml), CD28 (1µg/ml) and IL2 (100U/ml)], overnight 
serum deprivated DERL2 cells with or without CD3, CD28 and IL2 activation and overnight 
serum deprivated SUDHL4 cells with or without BCR stimulation (anti-Fab’2, 4µg/ml) were 
analyzed for the expression of Syk, phospho-Syk (Tyr525/526)(C87C1) (Cell Signaling 
technology) and β-actin (Sigma Aldrich). Immunoblotting was done as previously described25. 
 
Apoptosis assay with a Syk inhibitor 
Normal activated γδ T cells were obtained as previously described26, DERL2 cells were plated at 
1,000,000 cells per well. They were incubated for 48 hours in the absence or presence of Syk 
inhibitor II (Merck Chemicals) at 2 different concentrations (40 and 60 µM). The number of 
apoptotic cells was determined by Annexin V+, 7AAD+ cells. For the normal activated γδ T 
cells, TCRVγ9 apoptotic cells were determined by measuring the pourcentage of TCRVγ9+ 
7AAD+ cells.           
 
RESULTS  
 
1 -  HSTL as a molecularly distinct entity irrespective of TCR γδ or αβ lineage  
Unsupervised consensus clustering of the expression profiles of 9 HSTL tumors and 41 
additional T-cell lymphoma samples including PTCL,NOS, angioimmunoblastic T-cell 
lymphoma (AITL) and NKTCL demonstrated a clear separation between HSTL and other T-cell 
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lymphomas entities. The HSTL cluster comprised two subgroups consisting of HSTL tissue 
samples and HSTL cells (sorted cells and cell line) (Figure 1). Interestingly, αβ and γδ HSTL 
clustered together. One non-hepatosplenic γδ T-cell lymphoma case (PTCL_20) with nodal 
presentation clustered within the NKTCL branch.  
On supervised analysis, αβ and γδ HSTL appeared to have a highly similar gene 
signature. As illustrated in supplemental figure S1, a similar level of transcripts of NK cell-
associated molecules including killer immunoglobulin-like receptors (KIRs) were found in 
HSTL, irrespective of αβ or γδ lineage. Besides the genes coding for the γδ and αβ TCR which, 
as expected, were the most differentially expressed between both groups, only a  small proportion 
of genes appeared overexpressed in γδ HSTL (LCK, SYT11, BCL2L11, KLRC1...) or 
downexpressed (CR1, TMPRSS3, ITGA9...) compared to αβ HSTL (Supplemental table S1). 
Comparison of HSTL gene expression profiles with that of either PTCL,NOS or NKTCL 
revealed similar proportions of differentially expressed genes (H1 Proportion, see Method S1)  of 
37% and 39% respectively), however in unsupervised clustering analysis, HSTL profiles 
appeared to be closer to that of NKTCL, another extranodal entity derived from cytotoxic cells, 
than that of PTCL,NOS and AITL.   
Compared to both PTCL, NOS and NKTCL, several T-cell associated transcripts encoding the γδ 
T-cell receptor (TCR) subunit were among the top genes overexpressed in HSTL. Two of the 
interesting genes found to be upregulated in HSTL were S1PR5, a gene known to be involved in 
the homing of NK cells into the spleen27 and ABCB1 encoding for the p-glycoprotein multidrug 
transporter (MDR1). These findings were confirmed by qRT-PCR that demonstrated high S1PR5 
and ABCB1 transcripts in HSTL compared to PTCL,NOS and NKTCL (Figure 2).  Genes 
encoding KIRs and other NK cell-associated molecules (NCAM1, CD244) were specifically 
overexpressed compared to PTCL, NOS (Tables 2 and 3). 
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AIM1, reported as a tumor suppressor gene 28, was underexpressed in HSTL compared both to 
PTCL,NOS and NKTCL. The genes underexpressed in HSTL compared to PTCL,NOS included 
genes encoding TFH–associated molecules (CXCL13, ICOS, CD200, CXCR5), others involved in 
immunomodulation (IDO1, IL4I1) as well as CD5, a T-cell surface antigen known to be absent in 
HSTL cells. 
 
2 – Candidate genes relevant to HSTL pathogenesis  
To search for candidate genes relevant to the pathogenesis of HSTL, we compared HSTL 
signature to that of normal γδ T cells. A selection of significantly overexpressed and 
underexpressed genes distinguishing HSTL from normal activated or resting γδ T cells is 
summarized in Table 4 (p<0.01). Among the most overexpressed genes in HSTL were those 
related to NK-cell associated molecules such as KIRs, KLR, CD244 and NCAM1. The other 
overexpressed genes were related to oncogenes (FOS,  VAV3, MAF and BRAF), cell adhesion 
(VCAM1, CD11d, ICAM1), tyrosine kinases (SYK), signal transduction (SPRY2, RHOB, 
MAP4K3, SPRY1), the sonic hedgehog pathway (GLI3, PRKAR2B, PRKACB and PRKAR1A), the 
WNT pathway (FRZB, TCF7L2, BAMBI, TLE1, CTNNB1, APC and FZD5) and S1PR5. 
Interestingly, many of these genes appeared to be also overexpressed in HSTL sorted cells 
compared to normal activated or resting cells γδ T cells (supplemental Table S1). This was the 
case for genes encoding FOS, VAV3, RHOB, S1PR5 and NK-cell associated molecules indicating 
that their overexpression could be attributed to the neoplastic cells. These findings were 
confirmed by qRT-PCR analysis (Figure 2) demonstrating overexpression of FOS, RHOB, VAV3, 
S1PR5 and KIR3DS1 mRNAs in HSTL sorted cells, and to a lesser extent in HSTL tissues, in 
comparison with normal γδ T cells. Furtheremore, another oncogene FOSB (belonging to the 
AP1 family) was overexpressed in HSTL cells compared to activated γδ T cells. This finding was 
corroborated by qRT-PCR analysis (Figure 2D) and by immunohistochemistry evidencing the 
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presence of FosB-positive cells coexpressing CD2 or TIA1 in HSTL (Figure 3A). In addition, 
membrane CD56 (9/17) and cytoplasmic Syk (8/9) were demonstrated in the neoplastic cells 
infiltrating the sinuses in the spleen or bone marrow (Figure 3C and D).  
Genes associated with cytotoxicity (Granulysin, Granzyme H, Granzyme K, Granzyme B), 
cytokines (LTA, TNF, IFNG), the tumor suppressor AIM1 and CD5 were among genes those 
significantly underexpressed in HSTL compared to normal cell counterpart. Absence of 
expression of cytotoxic molecules such as Granzyme B (Table 1) and Granzyme H was shown by 
immunostaining (Figure 3H) whereas the dramatic reduction of AIM1 transcripts was 
demonstrated by qRT-PCR in both HSTL tissues and sorted cells compared to normal γδ cells 
(Figure 5A).  
  
3 – Biomarkers discriminating HSTL from other lymphomas and normal controls 
Expression of several genes in the molecular signature of HSTL appeared most likely to be 
attributed to the normal spleen signature. This is the case of  ICAM-1, VCAM-1 and CD163 gene 
products, whose expression was shown by immunohistochemistry to be restricted to non 
neoplastic cells, that is, endothelial cells (VCAM1, ICAM1) and macrophages (CD163). To build 
a biomarker list differentiating HSTL from other T-cell lymphoma entities and eliminating the 
observed microenvironmental signature, supervised tests (see Method S1 for details) were 
performed between HSTL and other lymphomas (i.e. AITL, PTCL,NOS and NKTCL), HSTL 
and control samples (i.e. normal lymph nodes, spleen, γδ T cells, B cells) as well as between 
HSTL obtained from tissues and cell suspensions. This yielded a list of 54 genes distinguishing 
HSTL from other lymphomas entities and normal controls (Supplemental Figure S2 and tables 
S2, S3 and S4). Among these genes were those encoding KIR molecules (KIR3DS1), CD244, 
DTNBP1 and S1PR5. The application of this list of biomarkers to an independent series of 
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lymphoma samples (including 4 HSTL, 15 AITL and 11 PTCL,NOS) using a different 
plateform17 allowed discrimination of HSTL from other PTCLs (supplemental Figure S3). 
 
 
4 – Relevant pathways and genes potentially involved in HSTL resistance to therapy  
Pathways analyses showed significant enrichment of a number of pathways which are involved in 
cancer development or can be the target of innovative treatments, such as VEGF, MAP kinase, 
JAK-STAT, mTOR, Notch signaling pathways, cytokine-cytokine receptor interaction, cell 
adhesion (Table 6 and supplemental table S5). The Wnt signature was found deregulated but 
activation of the pathway was not supported by immunohistochemistry since the expression of β-
catenin was restricted to endothelial cells. Consistent with previous findings17, pathways related 
to NK-cell mediated cytotoxicity were among the most differentially expressed compared to 
other T-cell lymphoma entities and normal γδ T cells (Figure 4A). Furthermore, as illustrated in 
figure 4B, many genes in the TCR signaling pathway (VAV3, BCL10), and linked to the AP1 
pathway (FOS) were enriched in HSTL compared to PTCL,NOS and NKTCL. These finding 
were supported by the high levels of VAV3, FOS, FOSB transcripts demonstrated by qRT-PCR, 
and  by immunohistochemical detection of Bcl-10 in the neoplastic cells of all investigated  
HSTL (5/5) (Figure 3D). Significant enrichment of genes in the pathways of Sprouty regulation 
of tyrosine kinase and the Sonic Hedgehog signaling [such as genes for the composition of 
cAMP-dependent kinase (PKA)(PRKAR2B, PRKAR1A and PRKACB), the transcription factor Ci 
(GLI3), the receptor patched (PTCH1) and GSK3B] were found in HSTL (Figure 4). 
Interestingly, several genes in the multidrug resistance signalling pathways (ABCB1, GSTP1) 
were enriched in HSTL (Figure 4E) compared to PTCL, NOS and NKTCL as well as PRDM1, 
another gene reported to be associated to resistance to therapy in PTCLs29. High levels of ABCB1 
transcripts were confirmed by qRT-PCR (Figure 2B) and expression of GSTP1 and Blimp-1 was 
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demonstrated by immunohistochemistry in HSTL cells of all evaluated cases, as well as in 
DERL2 cells (Figures 3). As illustrated in figure 4F, HSTL were closer to activated γδ T cells 
than resting γδ T cells with respect to the expression of cell cycle-related genes. 
 
5 – Isochromosome 7 q is the main recurrent genomic aberration in HSTL  
The aCGH findings confirmed recurrent isochromosome 7q in 4 of the seven tested cases (60%), 
with only few other alterations comprising trisomy 8 as previouly reported 9, loss of 10p arm and 
more focal alterations (-14q,+15q, -18q -21q, -22q) in 2 to 6 cases (30-85%)(Supplemental figure 
S4). In order to determine whether iso7q impacts on the molecular signature, we analysed the 
mean expression of genes located on the 7p and 7q arms for each sample (Supplemental figure 
S5). This analysis clearly showed overexpression of 7q and down expression of 7p genes in all 
cases with iso7q aberration as well as in 2 additional cases (HSTL_08, HSTL_09) for which the 
iso7q status was unknown (absence of aCGHa and FISH data), one of which could be 
subsequently demonstrated as iso7q by FISH (HSTL_09). To identify potential candidate genes 
involved in iso7q, we further compared the expression level of iso7q+ HSTL cases to normal 
controls (i.e. activated γδ T cells). Among the most repressed genes on 7p arm were CYCS, 
IKZF1 associated to regulation of apoptosis and HUS1, CBX3 involved in DNA repair, while the 
most overexpressed genes on 7q arm included the putative oncogene  PTPN12 (Supplemental 
Table S1).  Moreover, pathway analysis comparing iso7q+ HSTL to activated or resting γδ T 
cells showed a significant enrichment of apoptosis-related pathways (Supplemental Table S5). 
 
6 – AIM1 is methylated in HSTL  
AIM1 (absent in melanoma 1), initially described as a tumor suppressor gene deleted in 
melanoma, was subsequently found to be deregulated in NKTCL28,30. Here we show significant 
downexpression of AIM1 mRNA in HSTL and DERL2 cells. Low levels of AIM1 mRNAs were 
confirmed by qRT-PCR in HTSL primary tumors and in DERL2 cells compared to normal γδ T 
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cells (Figure 5A). We further searched for genetic alterations underlying AIM1 downregulation. 
In the absence of genomic imbalance in AIM1 locus at 6q21 in aCGH data, we asked whether 
AIM1 downregulation in HSTL could be the result of methylation as already reported in other 
hematologic malignancies such as myeloma and NKTCL30,31. The promoter methylation status of 
AIM1 was analysed in the HSTL-derived cell line, DERL-2. Sequencing of AIM1 on bisulfite-
treated DNA revealed methylation in both CpG islands (Figure 5B). Furthermore, the treatment 
of DERL2 cells with AIM1 methylated promoter with the DNA demethylating agent decitabine 
with or without TSA resulted in a 2-3 fold increase in AIM1 mRNA level compared to untreated 
cells, supporting that AIM1 downexpression in HSTL could be reversed by demethylation (Figure 
5C). Interestingly, the number of DERL2 apoptotic cells was increased after decitabine treatment 
(Figure 5D). 
 
7 – Syk as a candidate target for pharmacologic inhibition in HSTL 
Whereas normal mature T lymphocytes lack Syk expression, Syk protein has been recently 
reported to be aberrantly expressed in many PTCLs32. GEP analysis revealed overexpression of 
SYK mRNA in HTSL tissues, in HSTL sorted cells and in the DERL2 cell line compared to 
normal γδ T cells (Figure 6A). We further demonstrated Syk expression by neoplastic HSTL cells 
and DERL2 cells, by immunohistochemistry and western blot (Figures 3B, 6B and 6C). Because 
expression of Syk does not provide information on its activity, we analyzed the phosphorylation 
status of Syk in DERL2 cells using a phospho-specific anti-Syk (Tyr525/526) antibody. Syk was 
constitutively activated in DERL2 cells (Figure 6C). The mechanism leading to Syk activation is 
unclear as neither SYK amplification nor ITK-SYK fusion was detected by FISH analysis in 
DERL2 cells (data not shown). To determine whether Syk could contribute to the growth and 
survival of neoplastic HSTL cells, a chemical anti-Syk agent was used to inhibit Syk activity in 
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DERL2 cells. Syk inhibition induced an significant increase in apoptosis in a dose-dependent 
manner in DERL2 cell line as compared to normal activated γδ T cells (Figure 6D).  
 
DISCUSSION  
HSTL is a rare and distinct PTCL entity of unknown pathogenesis. The disease is characterized 
by a peculiar distribution of the neoplastic cells, most often of γδ T-cell derivation, within sinuses 
of the spleen, the liver and bone marrow and by the clinical fatal outcome. Previous scarce 
reports showed that HSTL has a distinct gene signature13,17. Taking advantage of the exceptional 
availability of samples enriched in tumor cells, we show by consensus clustering that HSTL 
expression profiles clustered in a single branch independently of the spleen, marrow or blood 
origin of the diagnostic samples indicating that this signature is independent of the 
microenvironment. The distinct signature was further confirmed when a gene list was constructed 
by eliminating the signature of the normal spleen and lymph nodes. HSTL was initially reported 
as of γδ T-cell derivation but similar cases with a αβ phenotype have been later reported. In the 
present study, we show that two cases of HSTL with a αβ phenotype had a gene signature and 
also a genomic profile which were highly similar to the classical γδ HSTL variant providing 
strong molecular arguments for grouping γδ and αβ HSTL as a single entity as proposed in the 
current WHO classification8. The similar αβ and γδ HSTL molecular signature was largely 
contributed by genes implicated in cytotoxic T- and NK-cell function and development, 
suggesting that both αβ and γδ variants are derived from subsets of cells of the innate immune 
system8,33,34. Indeed, a subset of αβ T cells, referred as NK/T cells, share characteristics with NK 
cells and γδ T cells including expression of CD161 (KLRB1), CD16, CD56, KIRs molecules and 
participate with NK cells and γδ T cells in the innate immune system35. γδ T cells can accumulate 
in immunosuppressed patients and in the setting of chronic antigen stimulation. Expansion of γδ 
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T cells has especially been reported in patients with kidney transplantation, systemic lupus, 
Hodgkin lymphoma or malaria4 and more recently also after treatment with anti-TNF agents36. 
The elective distribution of the neoplastic cells within the sinuses and sinusoids of the 
bone marrow, spleen and liver is remarkable and accounts for the peculiar clinical presentation of 
HSTL with hepatosplenomegaly and cytopenia but without lymphadenopathy and leukemic 
pictures. Interestingly, one of the gene with the highest fold change of expression compared to 
PTCL,NOS and NKTCL and to a lesser extend in normal γδ T cells was Sphingosine-1-
phosphatase receptor 5 (S1PR5). S1PR5 encodes a member of the family of S1P receptors known 
to be involved in T- and B-cell exit from lymphoid organs 37. S1PR5 is preferentially expressed 
by mature CD56dim human NK cells38 and is involved in NK cell trafficking in steady-state and 
inflammatory situations. It has been reported that S1PR5-deficient mice have defective homing of 
NK cells to blood and spleen 27,38. Although the role of S1PR5 in γδ T cells is uncharacterized, 
the high level of S1PR5 mRNA in HSTL might explain the peculiar distribution and 
accumulation of neoplastic γδ cells in the spleen and bone marrow, preventing tumor cells from 
exiting sinusoids. Whether cell-cell interaction involving the cell adhesion molecule LFA1 
(CD11a) expressed by HSTL cells and VCAM1 expressed by splenic sinusoidal cells could also 
play a role in the clinicopathologic picture of the disease remains to be determined. 
Although our GEP findings were based on the  comparison with normal blood γδ T cells 
and not with splenic γδ T cells, the down or overexpression of selected genes compared to normal 
splenic γδ T cells was validated by qRT-PCR. From the present study it appears that several 
candidate genes involved in distinct pathways (i.e. TCR signalling, cell cycle, sonic hedgehog, 
sprouty regulation of tyrosine kinase pathways and multi-drug resistance) could potentially be 
associated with the pathophysiology of HSTL. One of the genes we found overexpressed in 
HSTL is MDR-1, whose expression was significant for this lymphoma upon comparison with 
normal γδ T cells, PTCL,NOS and NKTCL. The P-Glycoprotein (P-gp), encoded by MDR-1, is 
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able to export drugs out of the cytoplasm, thus reducing the intracellular accumulation of 
cytotoxic drugs. P-gp has been reported to be overexpressed and associated with poor outcome in 
various hematological malignancies including NKTCL and in DLBCL 39,40,41. Interestingly, 
sensitivity to aracytine is not influenced by P-gp overexpression in multidrug resistant cell 
lines42. Although HSTL is reported as a fatal disease, recent reports have described long 
survivors after cytarabine-based chemotherapy4. The present findings might provide a rationale 
for the use of cytarabine containing regimen in HSTL. In addition to P-gp expression we 
demonstrated that Glutathione-S-transferases (GSTs), another molecule involved with resistance 
to alkylating agents and anthracyclines43 was also expressed by the neoplastic HSTL cells (as 
shown by immunohistochemistry). One could hypothesise that the combination of P-gp and GST-
pi expression might contribute to the resistance to anthracyclin-based chemotherapy regimen of 
HSTL and its poor outcome. High levels of GST-pi are reported in neoplastic cells of mantle cell 
lymphoma and DLBCL44,45 and are correlated with poor prognosis in DLBCL44. The role of 
transcription factor Blimp-1 in PTCL is unclear. We show here that PRDM1 is expressed at 
mRNA and protein level in HSTL cells. While inactivation of PRDM1 through epigenetic 
mechanisms has been recently reported in NKTCL suggesting a role as tumor suppressor 
gene30,46, its expression has been associated with chemoresistance in T-cell lymphoma29.  
Tumor development is a multistep process involving deregulation of oncogenes and tumor 
suppressor genes (TSG). To date, no oncogene or TSG has been identified in HSTL. AIM1 is a 
gene whose expression is altered in association with tumor suppression in a model of human 
melanoma28. It is frequently deleted or methylated in several solid tumors and in myeloma and 
more interestingly NK cell lines14,30,31. Altogether, these data and our findings that AIM1 is 
dramatically reduced in HSTL most likely due to promoter methylation suggest that AIM1 might 
play a role as a TSG in HSTL oncogenesis and provide rationale for testing demethylating agents 
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in this disease.  Our expression data also suggests that the recurrent iso7q aberration in HSTL 
could target putative TSG and oncogenes, including IKZF1 and PTPN12. 
With respect to potential target for novel therapies in HSTL, we also show here Syk 
expression by neoplastic HSTL cells with constitutive activation in DERL2 cells compared to 
normal T cells. Syk is a protein tyrosine kinase involved in B-cell receptor signaling and its 
activation is associated with cell growth and survival in B-cell lymphomas 47,48. Normal mature T 
lymphocytes lack Syk expression 49. However, Syk protein has been recently reported as a feature 
common to most PTCLs, which potentially represents a novel therapeutic target, since, in 
addition to its aberrant expression in many PTCLs, inhibition of Syk induces apoptosis and 
blocks proliferation in T-cell lymphoma cell lines32,49. An orally available Syk inhibitor is 
currently being tested for B-cell lymphomas in a phase I/II clinical trial, with encouraging 
results50. In view of the findings that Syk inhibition induced apoptosis in DERL2 cells in a dose-
dependent manner, Syk could also be a potential candidate target for pharmacologic inhibition in 
HSTL. 
In conclusion, we show that the distinctive molecular signature of HSTL partly reflects 
the ontogeny and might explain several clinicopathologic features of the disease including the 
homing to sinusoids of the spleen and bone marrow. The study highlights emerging oncogenic 
pathways, potentially implicated in the pathophysiology of the disease. It may offer rationale for 
exploring new therapeutic options such as tyrosine kinase inhibitors and demethylating agents in 
these patients. Finally, this study also provides additional molecular arguments for grouping αβ 
and γδ HSTL as a single distinct entity.  
 
ACKNOWLEDGEMENTS 
This work is part of the Carte d’Identité des Tumeurs (CIT) program (http://cit.ligue-
cancer.net/index.php/en) from the Ligue Nationale Contre le Cancer and of the Tenomic project 
19 
supported by a Programme Hospitalier de Recherche Clinique  and the Institut National du 
Cancer (INCa). This work was supported by the Institut National de la Santé et de la Recherche 
Médicale (INSERM), the Institut National du Cancer (INCa), the Plan cancer of the Belgian 
government, and the Association pour la Recherche Thérapeutique, Génétique et Immunologique 
dans les Lymphomes (ARTGIL). M.T. was supported by the Fondation pour la Recherche 
Médicale (DEQ 2010/0318253). We are extremely thankful for the contributions made by 
Christelle Thibault from the IGBMC platform (Affymetrix : Philippe Kastner). We also thank Joe 
A. Trapani for providing antibodies, L. Del Vecchio for providing DERL2 cell line, Francois 
Radvanyi for critical opinion in data interpretation, Jérôme Cuvillier and Nadine Vailhen from 
GELAP, and Virginie Fataccioli and Maryse Baia for their technical assistance  
Appendix : List of contributors to the TENOMIC project : 
A. Martin, Hôpital Avicenne, Bobigny ; I. Soubeyran, P. Soubeyran, Institut Bergonié, Bordeaux; 
P. Dechelotte, A. Pilon, Pr O.Tournilhac, Hôtel-Dieu, Clermont Ferrand ; P. Gaulard, MH 
Delfau, A Plonquet, C. Haïoun, Hôpital H Mondor, Créteil; T. Petrella, L. Martin, JN Bastié, O 
Casasnovas CHU, Dijon; B. Fabre, D. Salameire, R. Gressin, D. Leroux, MC Jacob CHU, 
Grenoble ; L. De Leval, B. Bisig, G. Fillet, C. Bonnet, CHU of Liège ; M.C. Copin, B. 
Bouchindhomme, F. Morschhauser, CHU, Lille ; B. Petit, A. Jaccard, Hôpital Dupuytren, 
Limoges, F. Berger, B. Coiffier, CHU Sud, Lyon ; T. Rousset, P. Quittet, G. Cartron, Hôpital Gui 
de Chauliac-St Eloi, Montpellier ; S. Thiebault, B. Drenou, Hôpital E. Muller, Mulhouse ; K. 
Montagne, S. Bologna, CHU de Brabois, Nancy ; C. Bossard, S. Le Gouill, Hôtel-Dieu, Nantes ; 
T. Molina, Hôtel-Dieu, Paris ; J. Brière, C. Gisselbrecht, Hôpital St Louis, Paris ; B. Fabiani, A 
Aline-Fardin, P. Coppo, Hôpital Saint-Antoine, Paris ; F. Charlotte, J. Gabarre, Hôpital Pitié-
Salpétrière, Paris ; J. Bruneau, D. Canioni, V. Verkarre, E Macintyre, V. Asnafi, O. Hermine,  R. 
Delarue, F Suarez, D. Sibon, JP Jaïs, Hôpital Necker, Paris ; M. Parrens, JP Merlio, E Laharanne, 
K. Bouabdallah, Hôpital Haut Lévêque, Bordeaux ; S.Maugendre-Caulet, P. Tas, T. Lamy, CHU 
Pontchaillou, Rennes ; JM Picquenot, F. Jardin, C. Bastard, Centre H Becquerel, Rouen ; M. 
Peoc’h, J. Cornillon, CHU, Saint Etienne ; L. Lamant, G. Laurent, Lucie Oberic, Hôpital Purpan, 
Toulouse ; J.Bosq, P. Dartigues, V. Ribrag, Institut G Roussy, Villejuif ; M. Patey, A. Delmer, 
Hôpital R. Debré, Reims ; JF Emile, K. Jondeau, Hôpital Ambroise Paré, Boulogne ; MC 
Rousselet, Mathilde Hunault, CHU, Angers ; C. Badoual, Hôpital européen Georges Pompidou, 
Paris ; C. Legendre, S. Castaigne, AL Taksin, CH Versailles, Le Chesnay ; J. Vadrot, A. Devidas, 
CH Sud francilien, Corbeil ;  Dr Gandhi DAMAJ, CHU Amiens, Hématologie Clinique. 
F Lemonnier, M Travert, INSERM , Créteil ;P Dessen, G Meurice, Institut G Roussy, Villejuif ; 
M Delorenzi, E Missiaglia, N Houhou, Swiss Institut of Bioinformatics, Lausanne ; F Radvanyi, 
E Chapeaublanc, Institut Curie, Paris ; S Spicuglia, CIML, Marseille ; J Soulier, Hôpital St Louis, 
Paris ; C Thibault, IGBMC, Illkirsch 
GELA/GOELAMS 
 
20 
AUTHORSHIP: 
Contribution: P.G. L.d.L and M.T. designed research; M.T., Y.H., A.d.R., N.M-G., Ja.B. and 
T.M. performed research; M.T., A.d.R., and P.G. analyzed and interpreted the data; L.d.L., Ja.B., 
J.B., B.P., and P.G. collected data; PG and A.d.R. supervised bioinformatics analyses , T.M. 
contributed vital analytical tools; M.T., A.d.R., L.d.L. and P.G. drafted the manuscript. 
Conflict-of-interest disclosure: The authors declare no competing financial interests. 
 
Correspondence: Philippe Gaulard, MD, Département de Pathologie and Inserm U955, Hôpital Henri 
Mondor, 94010 Créteil, France; e-mail : philippe.gaulard@hmn.aphp.fr. 
 
References 
1. Gaulard P, Bourquelot P, Kanavaros P, et al. Expression of the alpha/beta and 
gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a 
subset of gamma/delta T-cell lymphomas. Am J Pathol. 1990;137:617-628. 
2. Farcet JP, Gaulard P, Marolleau JP, et al. Hepatosplenic T-cell lymphoma: 
sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. 
Blood. 1990;75:2213-2219. 
3. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a 
distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood. 1996;88:4265-
4274. 
4. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare 
clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 
2003;102:4261-4269. 
5. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma 
associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr 
Gastroenterol Nutr. 2007;44:265-267. 
6. Macon WR, Williams ME, Greer JP, Cousar JB. Paracortical nodular T-cell lymphoma. 
Identification of an unusual variant of peripheral T-cell lymphoma. Am J Surg Pathol. 
1995;19:297-303. 
7. Suarez F, Wlodarska I, Rigal-Huguet F, et al. Hepatosplenic alphabeta T-cell lymphoma: 
an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic 
T-cell lymphoma. Am J Surg Pathol. 2000;24:1027-1032. 
8. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of 
Haematopoietic and Lymphoid Tissues. IARC: Lyon. 2008. 
9. Wlodarska I, Martin-Garcia N, Achten R, et al. Fluorescence in situ hybridization study of 
chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common 
abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes 
Cancer. 2002;33:243-251. 
10. Bennett M, Matutes E, Gaulard P. Hepatosplenic T cell lymphoma responsive to 2'-
deoxycoformycin therapy. Am J Hematol. 2010;85:727-729. 
21 
11. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral 
T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma 
(AITL) and follicular helper T (TFH) cells. Blood. 2007;109:4952-4963. 
12. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T 
cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin 
Invest. 2007;117:823-834. 
13. Iqbal J, Weisenburger DD, Chowdhury A, et al. Natural killer cell lymphoma shares 
strikingly similar molecular features with a group of non-hepatosplenic gammadelta T-cell 
lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. Leukemia. 
2011;25:348-358. 
14. Huang Y, de Reynies A, de Leval L, et al. Gene expression profiling identifies emerging 
oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood. 
2010;115:1226-1237. 
15. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis 
in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. 
Blood. 2010;115:1026-1036. 
16. Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies 
molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25:1560-1570. 
17. Miyazaki K, Yamaguchi M, Imai H, et al. Gene expression profiling of peripheral T-cell 
lymphoma including gammadelta T-cell lymphoma. Blood. 2009;113:1071-1074. 
18. Delfau-Larue MH, Dalac S, Lepage E, et al. Prognostic significance of a polymerase 
chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with 
mycosis fungoides. Blood. 1998;92:3376-3380. 
19. Kanavaros P, Farcet JP, Gaulard P, et al. Recombinative events of the T cell antigen 
receptor delta gene in peripheral T cell lymphomas. J Clin Invest. 1991;87:666-672. 
20. Correia DV, d'Orey F, Cardoso BA, et al. Highly active microbial phosphoantigen induces 
rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human 
gammadelta T-cells. PLoS One. 2009;4:e5657. 
21. Zhang Y, Ohyashiki JH, Shimizu N, Ohyashiki K. Aberrant expression of NK cell 
receptors in Epstein-Barr virus-positive gammadelta T-cell lymphoproliferative disorders. 
Hematology. 2010;15:43-47. 
22. Di Noto R, Pane F, Camera A, et al. Characterization of two novel cell lines, DERL-2 
(CD56+/CD3+/Tcry5+) and DERL-7 (CD56+/CD3-/TCRgammadelta-), derived from a single 
patient with CD56+ non-Hodgkin's lymphoma. Leukemia. 2001;15:1641-1649. 
23. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation 
of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459:717-721. 
24. Caron G, Le Gallou S, Lamy T, Tarte K, Fest T. CXCR4 expression functionally 
discriminates centroblasts versus centrocytes within human germinal center B cells. J Immunol. 
2009;182:7595-7602. 
25. Travert M, Ame-Thomas P, Pangault C, et al. CD40 ligand protects from TRAIL-induced 
apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP 
and Bcl-xL. J Immunol. 2008;181:1001-1011. 
26. Capietto AH, Martinet L, Fournie JJ. Stimulated gammadelta T cells increase the in vivo 
efficacy of trastuzumab in HER-2+ breast cancer. J Immunol. 2011;187:1031-1038. 
27. Jenne CN, Enders A, Rivera R, et al. T-bet-dependent S1P5 expression in NK cells 
promotes egress from lymph nodes and bone marrow. J Exp Med. 2009;206:2469-2481. 
28. Ray ME, Su YA, Meltzer PS, Trent JM. Isolation and characterization of genes associated 
with chromosome-6 mediated tumor suppression in human malignant melanoma. Oncogene. 
1996;12:2527-2533. 
22 
29. Zhao WL, Liu YY, Zhang QL, et al. PRDM1 is involved in chemoresistance of T-cell 
lymphoma and down-regulated by the proteasome inhibitor. Blood. 2008;111:3867-3871. 
30. Iqbal J, Kucuk C, Deleeuw RJ, et al. Genomic analyses reveal global functional 
alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell 
malignancies. Leukemia. 2009;23:1139-1151. 
31. de Carvalho F, Colleoni GW, Almeida MS, Carvalho AL, Vettore AL. TGFbetaR2 
aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. 
Int J Cancer. 2009;125:1985-1991. 
32. Feldman AL, Sun DX, Law ME, et al. Overexpression of Syk tyrosine kinase in 
peripheral T-cell lymphomas. Leukemia. 2008;22:1139-1143. 
33. Krenacs L, Smyth MJ, Bagdi E, et al. The serine protease granzyme M is preferentially 
expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin 
from lymphocytes involved in innate immunity. Blood. 2003;101:3590-3593. 
34. Morice WG, Macon WR, Dogan A, Hanson CA, Kurtin PJ. NK-cell-associated receptor 
expression in hepatosplenic T-cell lymphoma, insights into pathogenesis. Leukemia. 
2006;20:883-886. 
35. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 
2007;25:297-336. 
36. Kelsen J, Dige A, Schwindt H, et al. Infliximab induces clonal expansion of gammadelta-
T cells in Crohn's disease: a predictor of lymphoma risk? PLoS One. 2011;6:e17890. 
37. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and 
lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316:295-298. 
38. Walzer T, Chiossone L, Chaix J, et al. Natural killer cell trafficking in vivo requires a 
dedicated sphingosine 1-phosphate receptor. Nat Immunol. 2007;8:1337-1344. 
39. Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol. 2001;13:463-
469. 
40. Andreadis C, Gimotty PA, Wahl P, et al. Members of the glutathione and ABC-
transporter families are associated with clinical outcome in patients with diffuse large B-cell 
lymphoma. Blood. 2007;109:3409-3416. 
41. Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y. Immunohistochemical expression and 
clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, 
nasal type. Am J Hematol. 2008;83:795-799. 
42. Michelutti A, Michieli M, Damiani D, et al. Effect of fludarabine and arabinosylcytosine 
on multidrug resistant cells. Haematologica. 1997;82:143-147. 
43. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 
1994;54:4313-4320. 
44. Ribrag V, Koscielny S, Carpiuc I, et al. Prognostic value of GST-pi expression in diffuse 
large B-cell lymphomas. Leukemia. 2003;17:972-977. 
45. Bennaceur-Griscelli A, Bosq J, Koscielny S, et al. High level of glutathione-S-transferase 
pi expression in mantle cell lymphomas. Clin Cancer Res. 2004;10:3029-3034. 
46. Kucuk C, Iqbal J, Hu X, et al. PRDM1 is a tumor suppressor gene in natural killer cell 
malignancies. Proc Natl Acad Sci U S A. 2011. 
47. Pogue SL, Kurosaki T, Bolen J, Herbst R. B cell antigen receptor-induced activation of 
Akt promotes B cell survival and is dependent on Syk kinase. J Immunol. 2000;165:1300-1306. 
48. Gururajan M, Dasu T, Shahidain S, et al. Spleen tyrosine kinase (Syk), a novel target of 
curcumin, is required for B lymphoma growth. J Immunol. 2007;178:111-121. 
49. Wilcox RA, Sun DX, Novak A, Dogan A, Ansell SM, Feldman AL. Inhibition of Syk 
protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's 
lymphoma cell lines. Leukemia. 2010;24:229-232. 
23 
50. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib 
disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic 
leukemia. Blood. 2010;115:2578-2585. 
 
Table 1. Summary of clinical, pathological, immunohistochemical, and cytogenetic features 
of patients enrolled in the study. 
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HSTL_02   41 F HSTL γδ  Spleen Tissue + + - - - - - 
+  
* 
+ + - - 
+ 
R(Jδ)
G(β) 
iso7q (+) 
HSTL_03  73 F HSTL γδ Spleen Tissue + + - - - + - + + + + - + iso7q (-) 
HSTL_04  38 M HSTL γδ Spleen Tissue + nd - - - - + 
+ 
**  
- + - - + 
iso7q (+)  
trisomy 8  
HSTL_05  56 M HSTL 
αβ Spleen Tissue + nd - nd - - + - - - - - + iso7q (+) 
HSTL_06  53 F HSTL 
αβ Spleen Tissue + - - + - - + - + + - - + iso7q (-) 
HSTL_08  24 F HSTL γδ Blood 
Cell 
suspension 
(no cell 
sorting) 
+ nd - + - - - + + + nd nd +  
HSTL_09  36 M HSTL γδ Blood 
Cell 
suspension
(cell 
sorting 
CD56+) 
Purity 
77% 
+ + - + - - - + + + - nd + iso7q (+) 
HSTL_01  86 F HSTL γδ Spleen 
Cell 
suspension 
(cell 
sorting 
CD3+ 
CD56+) 
Purity 
84% 
+ + -/+ nd - - - + + + - - + iso7q (-) 
HSTL_10  67 M HSTL γδ Spleen Tissue + + - + - - - 
+ 
**  
- + - - + Iso7q (-) 
HSTL_07 
DERL2 30 M 
HSTL 
γδ Blood Cell line + + - + - +  + +   -  Iso7q (+) 
 
(*) HSTL_02 with a γδ HSTL phenotype at diagnosis disclosed a TCR-silent phenotype (βF1-, 
δTCR1-) at the time of analysis. 
 (**) δ chain rearrangement determination using a GC-clamp multiplex polymerase chain 
reaction (PCR)-δ-DGGE procedure 
(°) EBV investigation by in situ hybridization with EBERs probes and/or immunohistochemistry 
with LMP-1 antibody 
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Table 2: Selection of genes differentially expressed in HSTL primary tumors compared to 
PTCL,NOS with P-value less than 0.001. A complete list of genes is given in the 
supplemental table S1. 
 
Genes overexpressed in HSTL compared to PTCL,NOS   
 
Gene class and specific genes         Fold change 
NK cell associated molecules 
KLRC3         73,95 
KIR2DS2         33,03 
KLRD1         25,39 
CD16          11,83 
KIR3DL2         21,58 
KLRB1         17,52 
KIR3DS1         16,88 
KIR2DL2         20,35 
KIR3DL1         19,85 
KIR2DL3         16,35 
KIR3DL3         18,95 
KIR2DL1         17,42 
KLRC4         14,41 
NCAM         18,04 
CD244         10,65 
KIR2DS5         11,59 
KIR2DL5A         12,02 
KIR2DS1         9,47 
KIR2DS3         9,05 
KLRG1         9,39 
KLRC1 /// KLRC2        10,37 
KIR2DL3 /// KIR2DL4 /// KIR2DL5A     6,04 
CTSW (Cathepsin w)        6,76 
KLRK1         6,45 
Microenvironment 
Hemoglobin gamma        17,62 
Hemoglobin beta         15,13 
Hemoglobin alpha        14,39 
DEFA1 /// DEFA1B /// DEFA3      13,64 
CCL3 (MIP1)         4,44 
Chemokines 
CXCL7 (PPBP)        21,06 
CXCL6         8,96 
Multi Drug Resistance 
ABCB1 (MDR1)        11,72 
ABCB1 /// ABCB4        6,74 
Oncogenes 
MYBL1         18,81 
VAV3          3,86 
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Cell adhesion // Cell to cell interaction 
CD11d         48,35 
PGM5          6,90 
T cell receptor 
TRA@ // TRD@        13,22 
TARP // TRGC2        10,94 
Transcription factors 
TCF21          12,87 
PRDM16         7,86 
WT1          3,70 
Growth Factors 
IGFBP2         7,52 
AREG (amphiregulin)       8,96 
PDGFD         7,83  
Extracellular matrix interaction 
ADAMTS17         12,93 
Others 
S1PR5          49,99 
 
Genes downregulated in HSTL compared to PTCL,NOS  
 
Chemokines 
CCL19         0,011 
CXCL9         0,016 
CCL18         0,041 
CXCL10         0,044 
TFH signature 
CXCL13         0,057 
CD200         0,165 
ICOS          0,158 
CXCR5         0,246  
Immunomodulation 
IDO1          0,074 
IL4I1          0,160 
Tumor suppressor 
AIM1          0,195 
Others 
TIAM1         0,097 
CD5          0,209 
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Table 3: Selection of genes differentially expressed in HSTL primary tumors compared to 
NKTCL with P-value less than 0.001. A complete list of genes is given in the supplementary 
table S1. 
 
Genes overexpressed in HSTL compared to NKTCL  
 
Gene class and specific genes         Fold change 
 
NK cell associated molecules 
KLRB1         17,26 
KLRG1         6,81 
Microenvironment 
Hemoglobin delta        32,87 
Hemoglobin alpha        22,79 
Hemoglobin beta        19,46 
Hemoglobin gamma        15,18 
CD36          14,63 
T cell receptor 
TARP//TRGC2        11,12 
CD3D          7,34 
CD3G          6,89 
CD247 (CD3Z)        3,82 
Chemokines 
CXCL7         23,27 
CXCL6         10,73 
Transcription factors 
NR4A2         17,77 
TCF21          11,72 
GATA6         6,16 
PRDM16         5,99 
PRDM1         2,81 
Signal transduction 
SPRY2         9,87 
PLCB1         9,66 
MAP4K3         7,81 
RHOB          7,61 
SPRY1         5,59 
MAP3K5         2,35 
Wnt signaling 
TCF7L2         6,35 
TLE1          5,55 
Oncogenes 
VAV3          5,25 
FYN          4,29 
MAF          3,46 
Multi Drug Resistance 
ABCB1         2,54 
Growth factor 
PDGFD         9,26 
Cell adhesion/ extracellular matrix 
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CD11d         28,67 
ADAMTS17         9,53 
Apoptosis 
BCL2L11         4,59 
Cell cycle 
CCNL1         3,34 
CCND3         2,42 
Others 
S1PR5          39,64 
TMEM178         32,26 
TANC1         32,24 
FCRL3         20,27 
CD5L          14,89 
CXXC5         14,83 
 
Genes downregulated in HSTL compared to NKTCL  
 
Cytotoxic molecules 
Granzyme B         0,15 
Granzyme K         0,21 
Chemokines 
CXCL10         0,05 
Apoptosis 
BIRC5          0,26 
Immunomodulation 
IL4I1          0,26 
Tumor suppressor 
AIM1          0,26 
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Table 4 : Selection of genes differentially expressed in HSTL primary tumors compared to 
normal γδ T cells with P-value less than 0.01. A complete list of genes is given in the 
supplementary table S1. 
 
Genes overexpressed in HSTL compared to normal γδ T cells with p<0.01 
Gene class and specific genes     Fold change 
         Activated Resting 
Oncogenes 
FOS *         6,50 
VAV3 °        3,52  3,67 
MAF           4,42 
NK cell associated molecules 
KIR2DS2 * °        13,98  16,63 
KLRC3 * °        11,33  14,87 
KIR3DL1//KIR3DL2 * °      9,56  11,16 
KIR2DL1 * °        8,90  7,57 
KIR2DL2 * °        8,60  8,85 
KIR2DS5 * °        7,26  5,19 
KIR3DS1 * °        7,03  6,34 
KIR2DL3 * °        6,83  9,06 
KIR2DL5A * °       6,40  6,09 
KIR3DL3 * °        5,75  6,51 
KLRC4 * °        5,70  5,17 
KIR2DS3 * °        5,69  6,34 
KIR2DS1 * °        5,00  5,17 
KIR2DS4 * °        3,23  3,67  
CD244 *        7,23  3,18 
NCAM1 *        6,27 
Microenvironment 
Hemoglobin beta       46,31  34,14 
Hemoglobin alpha       34,93  24,06 
CXCL12        31,57  27,39 
Immunoglobulin       26,29  21,08 
CD163        8,86 
Signal transduction 
SPRY2 * °        13,77  33,98 
RHOB * °        7,03 
MAP4K3 * °        5,96  9,18 
SPRY1* °         6,50  7,97 
Sonic hedgehog 
GLI3 *        8,86  5,94 
PRKAR2B *        8,25  3,15 
PRKACB °        3,25  3,75 
PRKAR1A °        2,80  7,63 
Tyrosine kinase 
SYK *         10,59  2,68 
Cell adhesion 
CD11d * °        37,57  33,11 
VCAM1        15,06  71,58 
ICAM1          5,71 
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Wnt pathways 
FRZB         14,01  14,19 
TCF7L2 *        10,96   
BAMBI        8,58  7,52 
TLE1 *        7,16  4,48 
CTNNB1 *        3,99  11,24 
APC         3,60  2,33 
FZD5         2,53  3,43   
Others 
S1PR5  *        8,16  3,51 
 
Genes downregulated in HSTL compared to normal γδ T cells with p<0.01 
 
Cytotoxic molecules 
Granulysin * °       0,03  0,03 
Granzyme H * °       0,03  0,05 
Granzyme B *       0,04  0,17 
Granzyme K * °       0,26  0,10 
Chemokines 
LTA *         0,02 
TNF         0,03 
IFNG *        0,03 
Tumor suppressor 
AIM1  * °        0,34  0,24 
Others 
CD5 * °        0,24  0,20 
 
* genes also differentially expressed in HSTL cells compared to normal activated γδ T cells. 
° genes also differentially expressed in HSTL cells compared to normal resting γδ T cells. 
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Table 5: Summary of immunohistochemical results 
 
 
HSTL 
(n=20) DERL2  
FosB 5*/14 - 
CD163 0/3 ND 
ICAM1 0/7 ND 
VCAM1 4°/12 ND 
Granzyme H 0/7 - 
Beta-catenin 0/5 ND 
Syk 8/9 + 
Blimp-1 7/7 + 
Bcl10 5/5 ND 
GSTP1 4/4 ND 
CD56 9/17 + 
 
 
° 2 with weak (equivocal) staining in TC.    
 
* Double immunostaining showing presence of FosB-positive lymphocytes coexpressing CD2 or 
TIA1 in 3 investigated cases 
ND : Not done 
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Table 6 : Selection of pathways differentially expressed in HSTL compared to PTCL, NOS, 
NKTCL or normal γδ T cells. 
 
 
Pathway name 
HSTL vs 
PTCL,nos 
HSTL vs 
NKTCL 
HSTL vs 
activated 
γδ T cell 
HSTL vs 
resting γδ 
T cell 
Globaltest 
P value 
Globaltest 
P value 
Globaltest 
P value 
Globaltest 
P value 
Biocarta 133   - Ras-Independent in NK cell-
mediated cytotoxicity 3.E-06 3.E-02 3.E-04 3.E-03 
KEGG 04650 - Natural killer cell mediated 
cytotoxicity 5.E-06 7.E-03 7.E-05 3.E-03 
KEGG 04370 - VEGF signaling pathway 6.E-06 1.E-03 2.E-04 3.E-03 
KEGG 04060 - Cytokine-cytokine receptor 
interaction 6.E-06 4.E-03 1.E-04 7.E-03 
Biocarta 131   - Phospholipase C Signaling 
Pathway 7.E-06 3.E-04 3.E-03 8.E-02 
Biocarta 140   - Selective expression of chemokine 
receptors during T-cell polarization 7.E-06 3.E-02 5.E-05 1.E-02 
Biocarta 506   - Sprouty regulation of tyrosine 
kinase signals 8.E-06 2.E-04 2.E-04 3.E-03 
KEGG 04310 - Wnt signaling pathway 1.E-05 7.E-04 2.E-04 3.E-03 
Biocarta 590   - Sonic Hedgehog (Shh) Pathway 1.E-05 5.E-03 6.E-05 3.E-03 
Biocarta 137   - Regulation of BAD 
phosphorylation 1.E-05 7.E-03 9.E-05 3.E-03 
KEGG 04010 - MAPK signaling pathway 1.E-05 3.E-03 2.E-04 3.E-03 
KEGG 04340 - Hedgehog signaling pathway 3.E-05 1.E-03 5.E-04 2.E-02 
Biocarta 586   - Multi-Drug Resistance Factors 1.E-05 5.E-03 2.E-02 Ns 
Biocarta 465   - Role of MEF2D in T-cell 
Apoptosis 3.E-05 1.E-03 6.E-04 3.E-03 
KEGG 04660 – T cell receptor signaling pathway 3.E-05 3.E-03 8.E-05 Ns 
KEGG 04630 - Jak-STAT signaling pathway 4.E-05 9.E-03 1.E-04 3.E-03 
KEGG 04620 - Toll-like receptor signaling 
pathway 5.E-05 7.E-03 5.E-04 7.E-03 
KEGG 04514 - Cell adhesion molecules (CAMs) 6.E-05 3.E-03 3.E-04 7.E-03 
KEGG 04210 - Apoptosis 7.E-05 1.E-02 1.E-04 3.E-03 
KEGG 04150 - mTOR signaling pathway 1.E-04 3.E-03 2.E-04 3.E-03 
KEGG 04330 - Notch signaling pathway 2.E-04 1.E-03 3.E-04 2.E-02 
KEGG 04670 - Leukocyte transendothelial 
migration 3.E-04 1.E-02 1.E-03 3.E-03 
KEGG 05200 - Pathways in cancer 3.E-04 2.E-02 5.E-04 3.E-03 
KEGG 04110 - Cell cycle 1.E-02 5.E-03 3.E-03 3.E-03 
KEGG 03050 - Proteasome 5.E-03 3.E-03 2.E-04 1.E-02 
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 FIGURE LEGENDS 
Figure 1: HSTL samples cluster separately to the other T-cell lymphomas, irrespective of 
their αβ or γδ T-cell lineage 
Unsupervised consensus clustering of gene expression profiles of 9 HSTL, 7 NKTCL, 16 
PTCL,NOS and 17 AITL tumor samples. Core clusters (C1, C2, C3, C4) are defined as groups of 
at least 5 samples being co-clustered in at least 14 of the 16 initial partitions (see M&M), and are 
individualized by the horizontal red line. Fisher exact test p-values for association between the 
consensus partition C1/C2/C3/C4 and sample’s annotations (Lymphoma.type, Material.type, 
TCR.type) are shown in red. 
Lymphoma.type : {H : Hepatosplenic T-cell lymphoma (HSTL); N :  NK/T-cell lymphoma, nasal 
type (NKTCL); A : Angioimmunoblastic T-cell Lymphoma (AITL); P : Peripheral T-cell 
lymphoma, not otherwise specified (PCTL,NOS)} 
Material.type { C: cell line; S : sorted tumor cells; T : tissue sample} 
TCR.type : T-cell Receptor type { A: alpha-beta ; G: gamma-delta}(NA: not available) 
 
Figure 2: Validation of selected genes by quantitative RT-PCR analysis. 
qRT-PCR analysis for S1PR5, ABCB1, FOS, FOSB, RHOB, VAV3 and KIR3DS1 in HSTL tissues 
(n=10), cells (n=3), PTCL,NOS (n=14) and NKTCL (n=6). The results are expressed as relative 
fold change compared with normal γδ T cells sorted from spleen. Values for each sample were 
normalized to GAPDH. Arbitrary value of 1 was assigned to normal γδ T cells. 
 
Figure 3: Validation of genes overexpressed in gene expression profiling by 
immunohistochemistry. 
Representative HSTL disclosed staining of neoplastic cells for (A) FOSB, (B) SYK, (C) CD56, 
(D) BCL10, (E) GSTP1 and (F-G) PRDM1. Panel G refer to DERL2 cells. Staining of NK cells 
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for (H) Granzyme H were observed. Images were captured with a Zeiss Axioskop2 microscope 
(Zeiss). Photographs were taken with an Olympus DP70 camera. Images were acquired with 
Olympus DP Controller 2002, and images were processed with Adobe Photoshop Version 7.0 
(Adobe Systems). Original magnification, ×400 (A-L).  
 
Figure 4: Cellular programs deregulated in HSTL: * correspond to resting γδ T cells. 
Representative molecular pathways, among those differentially expressed (as shown by 
enrichment analysis, see tables 6 and S5) in HSTL by comparison with NKTCL, PTCL,NOS and 
normal γδ T cells, are illustrated (A: Natural killer-cell mediated cytotoxicity; B: T-cell receptor 
signaling pathway; C: Sprouty regulation of tyrosine kinase signal pathway; D: Sonic hedgehog 
pathway; E: Multi-drug resistance factors and F: Cell cycle). For each line, green corresponds to 
the minimal intensity value (min), red corresponds to the maximal intensity value (max), and 
black corresponds to to (–max - min)/2. 
 
Figure 5: AIM1 is methylated  in HSTL DERL2 cell line 
(A) Real-time PCR quantification of AIM1 was evaluated in normal γδ T cells, HSTL tissues, 
HSTL cells, DERL2 cells, PTCL,NOS and NKTCL. The results are expressed as relative fold 
change compared with normal γδ T cells sorted from spleen. Each sample was normalized to 
GAPDH. (B) Localization of CpG islands (CpG1 and CpG2) in the AIM1 promoter and 
schematic representation of the sequenced genomic fragments including all CpG sites (vertical 
bars). Approximate spacing of the CpG dinucleotides is shown for the 44 CpGs of island 1 and 
the 119 CpGs of island 2 (Top). Ten representative clones from DERL2 cells are presented, only 
43 CpGs of island 2 were represented because of unmethylation of the first 76 CpGs (Left). 
Example of methylated cytosines after bisulfite-converted genomic DNA treatment (Right). 
Methylated CpG ,    ; Unmethylated CpG,    .  
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(C) Real-time PCR quantification of AIM1 was evaluated in DERL2 cells after 96 hours of 10µM 
or 40µM decitabine treatment (every 24hours) with or without 500nM TSA treatment for the last 
24 hours. (D) DERL2 cell line were cultured with or without 10µM or 40µM of decitabine for 96 
hours (decitabine was added every 24 hours). Cellular apoptosis was analyzed using 7AAD 
staining. 
 
Figure 6: SYK a potential candidate target for pharmacologic inhibition 
(A) Histogram representation of affymetrix datas of overexpressed SYK probe set in HSTL 
tissues, HSTL cells, normal γδ T cells and DERL2 cells. (B) Immunostaining of SYK in DERL2 
cell line. (C) Western blot analysis of Syk,  phosphorylated Syk tyr525/526 and loading control 
beta actin. (D) DERL2 cell line or normal activated γδ T cells were cultured with 40µM or 60µM 
of Syk inhibitor II or vehicle alone for 48 hours. Apoptosis was analyzed using 7AAD staining. 
For normal activated γδ T cells, TCRVγ9 apoptotic cells were determined by measuring the 
pourcentage of TCRVγ9+ 7AAD+ cells. * correspond to p<0.05. 
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